Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) COO Sells $43,500.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,175 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total value of $43,500.00. Following the transaction, the chief operating officer owned 62,371 shares in the company, valued at approximately $1,247,420. This trade represents a 3.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Jennifer Champoux also recently made the following trade(s):

• On Wednesday, June 17th, Jennifer Champoux sold 2,176 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $19.00, for a total transaction of $41,344.00.
• On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $43,500.00.

Monte Rosa Therapeutics Price Performance

Shares of GLUE opened at $22.28 on Friday. The company has a market capitalization of $1.88 billion, a PE ratio of -15.05 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a one year low of $4.12 and a one year high of $25.77. The company’s fifty day moving average price is $18.96 and its 200 day moving average price is $18.63.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on GLUE shares. JPMorgan Chase & Co. increased their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Guggenheim dropped their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Wells Fargo & Company dropped their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.50.

Institutional Trading of Monte Rosa Therapeutics

Hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its holdings in shares of Monte Rosa Therapeutics by 16.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares in the last quarter. Royce & Associates LP lifted its position in Monte Rosa Therapeutics by 8.3% in the third quarter. Royce & Associates LP now owns 11,024 shares of the company’s stock worth $82,000 after purchasing an additional 848 shares during the period. ProShare Advisors LLC lifted its position in Monte Rosa Therapeutics by 11.8% in the fourth quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock worth $178,000 after purchasing an additional 1,199 shares during the period. Finally, MetLife Investment Management LLC increased its holdings in Monte Rosa Therapeutics by 7.5% in the 4th quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock valued at $411,000 after buying an additional 1,831 shares during the period. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.